Articles tagged with Cancer
Researchers developed a new framework called SOLVE to overcome data challenges in precision cancer treatment. By jointly modeling known and unknown factors, SOLVE provides a robust tool for biomarker discovery and investigating tumor responses.
A study led by researchers from the Germans Trias i Pujol Research Institute has identified PARG as a new target to enhance chemotherapy in colorectal cancer. Inhibition of PARG significantly increases the cytotoxic effect of chemotherapy, leading to enhanced cell death and apoptosis in different colorectal cancer models.
Cancer cells tap into the nervous system's power grid by forming synaptic contacts with nerve cells, promoting tumor growth and spread. Venkataramani's research aims to repurpose the drug perampanel for glioblastoma treatment and develop gene therapy approaches to disconnect tumors from the nervous system.
Researchers developed miniature 3D tumor organoid models that closely mimic the human brain, revealing how glioblastoma interacts with surrounding brain cells and immune system. The models identified PTPRZ1 as a key regulator of tumor behavior, which helps determine its aggressiveness.
Researchers at Tohoku University designed optimized solvents that improve drug delivery to metastatic lymph nodes, promoting blood flow and expanding the lymphatic sinus as a drug pathway. These findings support the clinical application of Lymphatic Drug Delivery Systems (LDDS) in cancer treatment.
Researchers at Brown University discovered that the shape of spheroid aggregates influences cell behavior, with cells invading outward from sharper ends. The study used fluorescent proteins to track cell movement and measured forces exerted by cells as they move.
A new AI-powered model predicts patient survival and risk stratification for spinal metastasis, allowing for more informed treatment decisions. The model achieved high predictive accuracy using large-scale clinical data from Japanese patients.
Researchers at UC San Francisco found that spindle fibers can repair themselves as they pull on DNA, ensuring accurate chromosome division. This self-repair mechanism replaces weak links with stronger ones, preventing errors that could lead to cancer or birth defects.
Researchers developed a novel way to identify aggressive cancer cells by observing how they physically interact with their environment. The new technology uses specially designed microscopic surfaces to distinguish between aggressive and less aggressive cells.
Researchers found that circadian regulation shapes tumor microenvironment and determines patient responses to immune checkpoint blockade therapies. Disrupting these rhythms can suppress immune responses and diminish treatment efficacy.
This review analyzes molecular mechanisms of DDR pathways in mediating chemotherapy resistance, elucidating correlations with BRCA1/2 deficiency and ATM/ATR signaling pathway dysregulation. The study presents a novel molecular synergy model between DDR regulation and Immune Checkpoint Blockade to enhance immunotherapy responses.
A real-world study compared LLMs to human physicians in challenging lung cancer cases, finding that LLMs excel in rare cases with high comprehensiveness and specificity scores. However, they struggle with refractory cases, where physicians' reasoning stability is crucial.
A study by Stanford Medicine researchers found that people with colorblindness have a 52% higher mortality rate over 20 years compared to those with normal vision due to delayed diagnosis. The study suggests that missing the early sign of blood in urine can lead to worse outcomes.
Researchers developed bioengineered lymphatic tissue (CeLyT) that restored functional lymph nodes in mice with secondary lymphedema. CeLyTs improved lymphedema symptoms by restoring lymphatic flow, filtration capacity, and immune cell populations.
Researchers summarize the role of metabolic reprogramming in driving prostate cancer progression, highlighting key regulators and inter-pathway crosstalk mechanisms. Novel targeted therapeutic strategies targeting glucose, glutamine, and lipid metabolism are proposed to overcome current treatment bottlenecks.
The study reveals that orphan non-coding RNAs (oncRNAs) exist across all major cancer types and can be used as digital molecular barcodes to capture cancer cell identity. The research also identifies oncRNAs that drive cancer progression, with some showing promise as biomarkers for monitoring patients.
The event highlighted urgent global risks and science-led solutions for antimicrobial resistance, trust in data, and AI-enabled sustainable cities. Experts emphasized the need for immediate actions against AMR, which could kill more people than cancer by 2050.
Smoking exposure induces tumor microenvironment promoting sorafenib resistance in HCC by modifying the 14-3-3η proteome. Arsenic trioxide suppresses tumor progression with synergistic effect when combined with sorafenib.
The report shows a notable increase in medication treatments, such as chemotherapy, immunotherapy, and hormone therapy, used before surgery to treat many cancers. Neoadjuvant systemic therapy increased notably for certain cancers, including gynecologic cancers, pancreatic cancer, and rarer abdominal lining cancers.
Scientists at UNIGE created an AI tool called MangroveGS that can accurately predict the risk of cancer metastasis and recurrence. The algorithm uses gene expression signatures from colon cancer cells to identify key factors influencing metastatic potential, paving the way for more precise care and discovery of new therapeutic targets.
A study published by the National Institutes for Quantum Science and Technology found that carbon-ion radiotherapy provided durable tumor control with minimal side effects while preserving breast appearance in carefully selected patients who were unable or unwilling to undergo surgery. The treatment resulted in excellent local control ...
Cancer mortality rates have decreased for breast cancer and leukemia, despite increasing incidence, while colorectal cancer has become the leading cause of death among US young adults. Colorectal cancer surpasses lung, breast, and prostate cancers as the leading cancer-related death in people under 50 years old.
The Ralph Lauren Corporate Foundation has awarded a grant to establish the UChicago Medicine Ralph Lauren Center, expanding access to high-quality cancer screening and care in Chicago's South Side. The new center will focus on personalized and comprehensive approaches to patient navigation and prevention services.
Scientists at Northwestern University have determined the three-dimensional structures of rye pollen's cancer-fighting molecules, secalosides A and B. This breakthrough opens the door to exploring how these molecules interact with the immune system and could inspire new approaches to cancer therapy.
SPARK Microgravity plans to build Europe's first dedicated commercial orbital cancer lab, allowing researchers to run experiments impossible on Earth. This will accelerate the path from discovery to therapy, with microgravity enabling 3D tumor growth and revealing new drug targets.
Researchers found that obesity and estrogen-based medications synergistically increase thrombotic risk by suppressing Protein S levels. This study offers new insights for cancer care, highlighting the need to monitor and prevent blood clots in patients with obesity or estrogen use.
Researchers found that Fusobacterium nucleatum accelerates tumor growth and increases cancer cell spread in animal models of human breast cancer, particularly in cells with BRCA1 gene mutations. The study reveals a connection between oral microbes and breast cancer risk and progression.
A new review proposes a two-stage model explaining how different determinants of aging interact to generate late-life disease. Early-life damage and late-life genetic activity are identified as key drivers of age-related illnesses.
Dr. Brian Leyland-Jones was a renowned breast cancer oncologist and translational research leader who played a pivotal role in advancing cancer therapies. He made himself available to patients in need, offering his expertise pro bono and guiding them through diagnoses and treatment options.
A national clinical trial found that abemaciclib, an oral cancer drug, may slow tumor growth in patients with aggressive meningiomas with specific genetic mutations. The trial showed promising results, with a median progression-free survival of 10 months and a median overall survival of 29 months.
Researchers at Penn Vet have shown that trained dogs can identify the odor of hemangiosarcoma, a malignant cancer of blood vessel cells, with an accuracy rate of 70%. Early detection could lead to better outcomes, including prevention of disease spread and earlier removal of the spleen or initiation of chemotherapy.
A new blood test has identified a protein signature linked to cancer in patients with non-specific symptoms. The test distinguishes cancer from other conditions with high precision and can help prioritize patients for further diagnostics.
A new study found that nearly half of Medicare Part D beneficiaries with cancer face high out-of-pocket prescription drug costs, often leading to delayed treatment initiation and poorer health outcomes. Enrolling in the Medicare Prescription Payment Plan (M3P) could reduce monthly payment volatility and mitigate cost-related nonadherence.
Researchers developed a highly sensitive blood test that can detect initial thrombin generation, a key trigger in blood clot formation. The test distinguishes between pathway-specific clotting abnormalities and suggests personalized treatment strategies, potentially predicting clinical outcomes.
Predictions for lung cancer death rates among EU and UK women indicate stabilization of mortality rates at 12.5 deaths per 100,000 in 2026. Lung cancer remains the leading cause of cancer death for both sexes in the EU, with mortality rates continuing to decline among men.
The Phase 2 ANDROMEDA trial combines two types of PSMA-targeted radiopharmaceuticals with stereotactic body radiotherapy to delay progression and minimize side effects in patients with oligorecurrent prostate cancer. Researchers aim to determine which approach provides the most durable cancer control.
A Purdue-developed mRNA therapy delivery system has shown promise in targeting bladder cancer cells with improved efficiency. The system, called LENN, can be freeze-dried and stored for several days without losing its biological activity.
Researchers summarize itaconate biology highlighting its chemical reactivity and therapeutic potential in treating infectious diseases, sepsis, autoimmunity, neurodegenerative disorders. Itaconate exerts biological effects through post-translational modifications, altering protein activity and signaling pathways
A research team at Goethe University Frankfurt has compiled a catalog of human E3 ligases and mapped their relationships, revealing family-specific functions. The study identifies 40 additional E3 ligases suitable for PROTAC development, expanding the range of tissues and diseases targeted by degradation therapies.
A major U.S. clinical trial has uncovered a genetic factor that may inform how to optimize the dosing of abiraterone, a widely used hormone treatment for advanced prostate cancer. Researchers found that men who carry a specific version of the gene SULT2A1 clear abiraterone from their bodies more slowly, which could affect how well it w...
A new study from Fox Chase Cancer Center confirms that preoperative radiation therapy does not reduce surgical complexity in patients with retroperitoneal sarcoma. The research suggests that most patients benefit from proceeding directly to surgery, as skipping radiation has no significant impact on tumor size or surgical outcomes.
Researchers have created a library of over 400 immune-related factors to reprogram rare immune cell populations. This technique allows for the systematic discovery of 'recipes' for specific immune cells, offering hope for unresponsive patients and advancing immunotherapy.
Researchers at the University of Florida have discovered a small compound produced by gut bacteria that doubles the response to lung cancer immunotherapy treatment in mice. The findings could lead to a new combination therapy that boosts patient responsiveness by 50% without adding invasive treatments.
A new blood test has been developed to predict which patients with lung cancer will benefit from the newly approved immunotherapy drug tarlatamab. The test, based on circulating tumor cells, correctly identified 85% of patients who responded to the drug and 100% of those who did not.
A machine learning model has identified the most important drivers of cancer survival in nearly all countries, highlighting factors such as national wealth, access to radiotherapy and universal health coverage. The model provides data-driven roadmaps for policymakers to prioritize resources and close survival gaps.
Researchers found that targeting lipid metabolism in tumors can lead to ferroptosis, a type of cell death dependent on fat molecules. This could pave the way for new cancer treatments that target specific mechanisms responsible for lipid processing by tumors.
A study funded by the National Cancer Institute aims to test a low-cost intervention using future-focused thoughts to help people quit smoking. The project will examine the effectiveness of episodic future thinking in reducing impulsivity and promoting healthier choices.
A deep learning model trained on stage II colorectal cancer whole slide images accurately identified features linked to recurrence risk. The study found the model surpassed clinical prognostic parameters in predicting patient outcomes.
Large language models (LLMs) provide treatment recommendations for early-stage hepatocellular carcinoma (HCC) that align with clinical guidelines. However, their performance is limited in late-stage disease, where they prioritize tumor factors over liver function. LLMs should be used as a supplement to clinical expertise.
The new program combines limb preservation, amputation care, and reconstructive solutions like osseointegration to improve identity, functional outcome, and quality of life for patients. Patients will receive coordinated, personalized, and expert care that supports their recovery and promotes sustained overall health.
Researchers from The University of Osaka discovered that loss of heterochromatin can trigger genetic changes leading to chromosomal rearrangements and diseases like cancer. Accumulation of R-loops at pericentromeric repeats was found to be a key mechanism in this process.
Aggressive triple-negative breast cancer fine-tunes its protein production through a previously unknown mechanism discovered by Umea University researchers. The study reveals that fibrillarin collaborates with RPS28 to create specialized ribosomes, leading to imbalance in protein production and driving cancer development.
Researchers at UC San Diego have discovered a previously unrecognized treatment target for triple-negative breast cancer (TNBC). Disrupting the activity of PUF60 causes widespread errors in gene processing, resulting in DNA damage and tumor cell death.
A new clinical trial, PAGODA, seeks to minimize treatment interruptions and help patients complete their chemotherapy as planned. The trial will test a structured plan to guide doctors in making small, proactive changes to chemotherapy doses to prevent treatment delays.
A Mass General Brigham study identifies new mutations that emerge in tumor cells following treatment, driving resistance in patients with different types of cancer. The researchers found two main categories of mutations: those impairing p53 function and others disrupting drug binding, highlighting a path forward for overcoming resistance.
A new study published in CANCER found that men are more likely to have advanced disease and high myeloma load at diagnosis compared to women. Men were also less likely to have low bone mineral density and had different chromosomal abnormalities, which may contribute to the sex disparity in multiple myeloma risk.
Researchers at MD Anderson have made significant advancements in cancer treatment, demonstrating the effectiveness of immunotherapy before and after surgery in improving lung cancer patient outcomes. Additionally, a new study shows promise in using CAR T cell therapy to treat large B-cell lymphoma, reducing relapse rates.
Researchers have identified a new class of molecules that specifically degrade the cancer-promoting enzyme IDO1, offering a potential solution to enhance checkpoint-based immunotherapy. These IDO1 degraders may overcome limitations of previous inhibitors and open new avenues for treating various types of cancers.
A global review of COVID-19 vaccination and infection cases found associations between the two and certain types of cancer. The study analyzed 69 publications and identified potential biological mechanisms, including immune responses and inflammation.
Researchers have developed a new way to boost the immune system's response to cancer by using specially engineered antibodies. The antibodies work by clustering multiple immune cell receptors, amplifying the signal that tells T cells to attack cancer cells.